Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Given Consensus Rating of “Hold” by Analysts

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) has been given an average recommendation of “Hold” by the ten analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $5.2188.

A number of equities research analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Tuesday, October 14th. Royal Bank Of Canada reduced their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating on the stock in a report on Tuesday, August 12th.

Insiders Place Their Bets

In related news, CEO Bernd Brust acquired 216,212 shares of Maravai LifeSciences stock in a transaction on Thursday, November 13th. The shares were bought at an average cost of $3.25 per share, with a total value of $702,689.00. Following the completion of the purchase, the chief executive officer directly owned 466,771 shares of the company’s stock, valued at $1,517,005.75. The trade was a 86.29% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders purchased 466,771 shares of company stock worth $1,511,699 over the last quarter. Insiders own 2.11% of the company’s stock.

Hedge Funds Weigh In On Maravai LifeSciences

Institutional investors and hedge funds have recently modified their holdings of the stock. CIBC Bancorp USA Inc. bought a new position in shares of Maravai LifeSciences during the 3rd quarter valued at approximately $33,000. Abel Hall LLC bought a new stake in Maravai LifeSciences in the third quarter worth $33,000. Quantessence Capital LLC purchased a new position in Maravai LifeSciences during the third quarter worth $31,000. Millennium Management LLC boosted its stake in Maravai LifeSciences by 77.2% during the third quarter. Millennium Management LLC now owns 439,703 shares of the company’s stock worth $1,262,000 after buying an additional 191,616 shares during the period. Finally, Epacria Capital Partners LLC increased its position in Maravai LifeSciences by 6.8% during the third quarter. Epacria Capital Partners LLC now owns 100,078 shares of the company’s stock valued at $287,000 after acquiring an additional 6,384 shares during the last quarter. Hedge funds and other institutional investors own 50.25% of the company’s stock.

Maravai LifeSciences Trading Down 6.6%

Shares of MRVI stock opened at $3.38 on Tuesday. The company has a current ratio of 5.29, a quick ratio of 4.56 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $864.30 million, a price-to-earnings ratio of -4.02 and a beta of 0.32. Maravai LifeSciences has a 12-month low of $1.66 and a 12-month high of $6.21. The stock’s 50-day moving average price is $3.24 and its 200-day moving average price is $2.71.

Maravai LifeSciences (NASDAQ:MRVI) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.02). The firm had revenue of $41.63 million for the quarter, compared to analysts’ expectations of $49.02 million. Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%. Equities research analysts predict that Maravai LifeSciences will post -0.24 EPS for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.